A share price of Candel Therapeutics Inc [CADL] is currently trading at $5.96, down -2.13%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CADL shares have lost -4.03% over the last week, with a monthly amount drifted -11.57%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Citigroup started tracking the stock with Buy rating on February 20, 2025, and set its price target to $25. On February 19, 2025, Canaccord Genuity initiated with a Buy rating and assigned a price target of $20 on the stock. BofA Securities started tracking the stock assigning a Buy rating and suggested a price target of $15 on February 07, 2025. H.C. Wainwright initiated its recommendation with a Buy and recommended $11 as its price target on December 02, 2022. BMO Capital Markets started tracking with a Outperform rating for this stock on November 19, 2021, and assigned it a price target of $18. In a note dated August 23, 2021, UBS initiated a Buy rating and provided a target price of $9 on this stock.
Candel Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $3.79 and $14.60. Candel Therapeutics Inc [NASDAQ: CADL] shares were valued at $5.96 at the most recent close of the market.
Analyzing the CADL fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -1.37 and Total Capital is -0.44. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.86 points at the first support level, and at 5.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.11, and for the 2nd resistance point, it is at 6.26.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Candel Therapeutics Inc [NASDAQ:CADL] is 7.04. In addition, the Quick Ratio stands at 7.04 and the Cash Ratio stands at 4.59.
Transactions by insiders
Recent insider trading involved Nichols William Garrett, Chief Medical Officer, that happened on Jul 28 ’25 when 937.0 shares were sold. Chief Medical Officer, Nichols William Garrett completed a deal on Jun 30 ’25 to sell 781.0 shares. Meanwhile, Officer WILLIAM GARRETT NICHOLS bought 3593.0 shares on Jun 30 ’25.
